Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study assesses the impact of an pea protein supplement with high iron bio-availability on iron status and exercise performance.
Female endurance athletes are susceptible to iron deficiency due to poor iron intake from diets or possibly because of destruction of red blood cells during foot-strike hemolysis. This study will evaluate the impact of 8-weeks of iron supplementation through consumption of a pea-protein power that has high iron bio-availability due to low phytate levels. This will be compared to consumption of regular iron protein powder and maltodextrin placebo by randomizing participants to three groups. Participants will be assessed at baseline and after 8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass and lean tissue mass).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pea power with high iron bio-availability | Experimental | Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day) |
|
| Pea powder | Active Comparator | Pea powder with normal phytate levels (7mg iron per day) |
|
| Placebo | Placebo Comparator | Placebo (maltodextrin) powder (0g iron per day) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low phytate pea powder | Dietary Supplement | Exercise performance with low phytate pea powder |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in ferritin levels | blood ferritin levels | Up to 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in maximal aerobic capacity | Maximal aerobic capacity (mL/kg/min) measured on a treadmill | Up to 8 weeks |
| Change from baseline in exercise time trial performance | Time (minutes) to complete 5 km running on a treadmill |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philip Chilibeck, Ph.D. | University of Saskatchewan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Saskatchewan | Saskatoon | Saskatchewan | S7N5B2 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37291968 | Derived | Shaw KA, Chilibeck PD, Lindsay DL, Warkentin TD, Ko J, Zello GA. Low phytic acid pea supplementation as an approach to combating iron deficiency in female runners: A randomized control trial. Nutr Health. 2025 Mar;31(1):293-301. doi: 10.1177/02601060231181605. Epub 2023 Jun 8. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018798 | Anemia, Iron-Deficiency |
| ID | Term |
|---|---|
| D000747 | Anemia, Hypochromic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C008315 | maltodextrin |
Not provided
Not provided
Not provided
Participants are being randomized to three groups for the 8-week intervention:
Not provided
Not provided
The powder supplements are being administered in a blinded manner. An individual who is separate from the rest of the research team will generate the allocation schedule and prepare the supplement packages so that participants, investigators, and outcome assessors are blinded. Statistical analysis will be blinded by coding of groups
| Regular pea powder | Dietary Supplement | Exercise performance with regular pea powder |
|
| Placebo (maltodextrin) | Dietary Supplement | Exercise performance with placebo (maltodextrin) |
|
| Up to 8 weeks |
| Change from baseline in hemoglobin levels | Blood hemoglobin concentration | Up to 8 weeks |
| Change from baseline in lean tissue mass | Lean tissue mass (kg) measured with dual energy X-ray absorptiometry | Up to 8 weeks |
| Change from baseline in fat mass | Fat mass (kg) measured with dual energy X-ray absorptiometry | Up to 8 weeks |
| D000090463 |
| Iron Deficiencies |
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |